| |
Omega-3 (n = 30)
|
Placebo (n = 30)
|
|---|
|
Age*, y
|
48.6 ± 7.6
|
48.8 ± 8.7
|
|
Gender*
|
|
Male, n (%)
|
9 (30)
|
6 (20)
|
|
Female, n (%)
|
21 (70)
|
24 (80)
|
|
Energy intake, kcal/d
|
1585.1 ± 572.8
|
1200.2 ± 295.5
|
|
MET, (h/d)
|
28.1 ± 4.2
|
27.7 ± 3.9
|
|
Height*, cm
|
160.4 ± 8.9
|
160.5 ± 8.2
|
|
Weight*, kg
|
78.0 ± 10.5
|
77.1 ± 12.5
|
|
BMI*, kg/m2
|
30.2 ± 3.6
|
29.8 ± 4.2
|
|
WC*, cm
|
106.7 ± 9.1
|
104.2 ± 9.8
|
|
HDL-c*, mg/dL
|
45.3 ± 8.9
|
46.5 ± 8.03
|
|
LDL-c*, mg/dL
|
95.9 ± 30.0
|
92.2 ± 22.2
|
|
TG*, mg/dL
|
151.6 ± 57.5
|
138.4 ± 51.8
|
|
TC*, mg/dL
|
166.0 ± 41.1
|
159.9 ± 29.3
|
|
AIP*
|
0.49 ± 0.22
|
0.44 ± 0.19
|
|
Castelli risk index I*
|
3.63 ± 0.9
|
3.41 ± 0.7
|
|
Castelli risk index II*
|
2.11 ± 0.6
|
1.97 ± 0.5
|
|
AC*
|
2.63 ± 0.9
|
2.41 ± 0.7
|
- P values are computed by independent t-test and data are expressed as mean ± standard deviation (SD), while for Gender is computed by chi-square test and data are expressed as number (percent)
- *: No significant difference was found between two groups at the baseline, except for energy intake (P = 0.002)
- NAFLD Non-alcoholic fatty liver disease, MET-h Metabolic equivalent task, BMI Body mass index, WC Waist circumference, HDL-c High density lipoprotein-cholesterol, TG Triglyceride, TC Total cholesterol, AIP Atherogenic index of plasma, AC Atherogenic coefficient
